CERo Therapeutics (OTCQB: CERO) has announced advancements to the CertainT-1 trial focused on patients with acute myeloid leukemia (AML).
According to CERo, following completion of the dose-limiting toxicity (DLT) observation period for the first cohort, a total of 4e6 cells/kg of CER-1236 was delivered to the first patient of the second cohort. This patient received a dose level four times higher than that administered to patients in the first cohort (1e6 cells/kg) and has completed the DLT observation period. In addition, the investigators provided a fourth additional dose to the second patient in the first cohort, who remains on study.
“In a statement, Chris Ehrlich, CEO of CERo, commented, “Enrollment and dosing are ongoing in our Phase 1 clinical trial of CER-1236. The first patient in the second cohort has received a higher cell dose, and safety monitoring is continuing. In addition, one patient in the first cohort has received an additional dose and remains on study. We are focused on the careful conduct of the dose-escalation phase and the systematic collection of safety data as the trial proceeds.”
